Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy

Hypertension

Volumn 41, Issue 3 II, 2003, Pages 824-829

  Kagiyama, Shuntaro ^a   Qian, Keping ^a   Kagiyama, Tomoko ^a   Phillips, M Ian ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antisense; Blood pressure; Gene therapy; Hypertrophy, left ventricular; Protein kinases; Receptors, epidermal

Indexed keywords

ANGIOTENSIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; BLOOD PRESSURE; GENE THERAPY; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED SHR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0037340170     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000047104.42047.9B     Document Type: Conference Paper

References (28)

1. Halkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med. 2002;112:126-134.
2. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens. 2002;15:9S-13S.
3. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a nonpressor mechanism. Hypertension. 1991;17:626-635.
4. Butcher RD, Schollmann C, Marme D. Angiotensin II mediates intracellular signaling in vascular smooth muscle cells by activation of tyrosine-specific protein kinases and c-raf-1. Biochem Biophys Res Commun. 1993;196:1280-1287.
5. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002;106:909-912.
6. Berecek KH, Schwertschlag U, Gross F. Alterations in renal vascular resistance and reactivity in spontaneous hypertension of rats. Am J Physiol. 1980;238:H287-H293.
7. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P, Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens. 1990;8:565-572.
8. Sambhi MP, Swaminathan N, Wang H, Rong H. Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II. Biochem Med Metab Biol. 1992;48:8-18.
9. Swaminathan N, Vincent M, Sassard J, Sambhi MP. Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Clin Exp Pharmacol Physiol. 1996;23:793-796.
10. Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension. 1998;31:50-56.
11. Aoyagi T, Izumo S. Hemodynamic overload-induced activation of myocardial mitogen-activated protein kinases in vivo: augmented responses in young spontaneously hypertensive rats and diminished responses in aged Fischer 344 rats. Hypertension. 2001;37:52-57.
12. Phillips MI, Zhang YC. Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol. 2000;313:46-56.
13. 1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation. 2000;101:682-688.
14. Phillips MI, Kimura B. Central nervous system and angiotensin in the development of hypertension. In: McCarty R, Blizard DA, Chevalier RL, ed. Handbook of Hypertension: Development of the Hypertensive Phenotype: Basic and Clinical Studies, vol 19. Amsterdam: Elsevier Science; 1999:383-411.
15. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol. 2000;20:2539-2545.
16. Kubo T, Ibusuki T, Saito E, Kambe T, Hagiwara Y. Vascular mitogen-activated protein kinase activity is enhanced via angiotensin system in spontaneously hypertensive rats. Eur J Pharmacol. 1999;372:279-285.
17. 2+-dependent mitogen-activated protein kinase activation in spontaneously hypertensive rat vascular smooth muscle defines a hypertensive signal transduction phenotype. Circ Res. 1996;78:962-970.
18. Wilkie N, Ng LL, Boarder MR. Angiotensin II responses of vascular smooth muscle cells from hypertensive rats: enhancement at the level of p42 and p44 mitogen activated protein kinase. Br J Pharmacol. 1997;122:209-216.
19. 1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens. 2001;19:553-559.
20. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EL. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2002;39:479-485.
21. Aoki H, Richmond M, Izumo S, Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000;347:275-284.
22. Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller SJ, Sugden PH. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res. 1996;78:954-961.
23. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2001;276:7957-7962.
24. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
25. Fujino T, Hasebe N, Fujita M, Takeuchi K, Kawabe J, Tobise K, Higashiyama S, Taniguchi N, Kikuchi K. Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc Res. 1998;38:365-374.
26. 1-adrenergic receptor antagonists. Toxicol Appl Pharmacol. 1999;160:289-296.
27. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol. 1999;276:H976-H983.
28. Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR. Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension. 1989;13:295-304.